Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.15420/AER.2016.20.3 http://scihub22266oqcxt.onion/10.15420/AER.2016.20.3 C5013151!5013151!27617088     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Arrhythm+Electrophysiol+Rev 2016 ; 5 (2): 102-9 Nephropedia Template TP {{tp|p=27617088|t=2016. Individualising Anticoagulant Therapy in Atrial Fibrillation Patients |pdf=|usr=}}{{27617088}} gab.com Text Individualising Anticoagulant Therapy in Atrial Fibrillation Patients JO: Arrhythm Electrophysiol Rev http://www.kidney.de/pget.php?&tw=1&pmid=27617088 #FOAvip Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have emerged as alternatives to VKAs for the prevention of stroke in patients with non-valvular atrial fibrillation. Four NOACS: dabigatran, apixaban, rivaroxaban and edoxaban, have received regulatory approval in Europe from the European Medicines Agency. Numerous factors can influence the decision to prescribe a NOAC, the most important of which are assessment of stroke and bleeding risks. Given the variation in design of the pivotal phase III clinical trials investigating the efficacy and safety of NOACs, and in the absence of head-to-head comparative data, it is impossible to recommend one NOAC over the other. However, NOACS offer the opportunity for individualised therapy based on factors such as renal function, age or patient/doctor preference for once- or twice-daily dosing regimens. Dose reduction of some NOACS should be considered in at-risk patient populations. Twit Text FOAVip Individualising Anticoagulant Therapy in Atrial Fibrillation Patients ????Arrhythm Electrophysiol Rev http://www.kidney.de/pget.php?&tw=1&pmid=27617088 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27617088 #FOAvip English Wikipedia <ref>{{Cite pmid|27617088}}</ref> Individualising Anticoagulant Therapy in Atrial Fibrillation Patients #MMPMID27617088 Alings M Arrhythm Electrophysiol Rev 2016[Aug]; 5 (2): 102-9 PMID27617088show ga Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have emerged as alternatives to VKAs for the prevention of stroke in patients with non-valvular atrial fibrillation. Four NOACS: dabigatran, apixaban, rivaroxaban and edoxaban, have received regulatory approval in Europe from the European Medicines Agency. Numerous factors can influence the decision to prescribe a NOAC, the most important of which are assessment of stroke and bleeding risks. Given the variation in design of the pivotal phase III clinical trials investigating the efficacy and safety of NOACs, and in the absence of head-to-head comparative data, it is impossible to recommend one NOAC over the other. However, NOACS offer the opportunity for individualised therapy based on factors such as renal function, age or patient/doctor preference for once- or twice-daily dosing regimens. Dose reduction of some NOACS should be considered in at-risk patient populations. äIndividualising Anticoagulant Therapy in Atrial Fibrillation Patients (epmc).pdf DeepDyve Pubget Overpricing